Niki BioSolutions, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Niki BioSolutions, Inc. (NIKI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $2.58 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-27.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-03-27
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|
| 2025-12-31 | $2.58M 20-F · filed 2026-03-27 | |
| 2025-06-30 | $1.88M 6-K · filed 2025-10-03 | |
| 2024-12-31 | -$1.13M 20-F · filed 2026-03-27 | |
| 2024-06-30 | -$1.22M 6-K · filed 2025-10-03 | |
| 2023-12-31 | -$3.01M 20-F · filed 2026-03-27 | |
| 2023-06-30 | -$4.54M 6-K · filed 2024-12-20 | |
| 2022-12-31 | -$3.25M 20-F · filed 2025-04-30 | |
| 2021-12-31 | $4.64M 20-F · filed 2024-04-30 | |
| 2020-06-30 | -$1.17M 6-K · filed 2020-09-02 | |
| 2019-06-30 | -$21.64M 6-K · filed 2020-09-02 |